Previous Close | 30.47 |
Open | 28.97 |
Bid | 28.87 x 4000 |
Ask | 28.87 x 4000 |
Day's Range | 28.30 - 29.40 |
52 Week Range | 28.30 - 54.93 |
Volume | |
Avg. Volume | 30,620,631 |
Market Cap | 163.238B |
Beta (5Y Monthly) | 0.58 |
PE Ratio (TTM) | 15.80 |
EPS (TTM) | 1.83 |
Earnings Date | Jan 29, 2024 - Feb 02, 2024 |
Forward Dividend & Yield | 1.64 (5.67%) |
Ex-Dividend Date | Nov 09, 2023 |
1y Target Est | 40.10 |
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine Comirnaty and the treatment Paxlovid -- saw its shares drop about 40%. This includes Pfizer's newer programs and what they may deliver in the future, as well as the company's valuation today. Is Pfizer a buy right now -- or a stock to avoid?
One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). Here are two other issues driving me toward hitting the "sell" button on this pharma stock. Since Albert Bourla took over as CEO in 2019, Pfizer has been on a buying spree.
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.